Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice

Circulation

Volumn 103, Issue 18, 2001, Pages 2277-2282

  Cyrus, Tillmann ^a   Praticò, Domenico ^a   Zhao, Lei ^a   Witztum, Joseph L ^b   Rader, Daniel J ^a   Rokach, Joshua ^c   FitzGerald, Garret A ^a   Funk, Colin D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Florida Institute of Technology   (United States)

Author keywords

Atherosclerosis; Enzymes; Lipids; Lipoxygenase

Indexed keywords

APOLIPOPROTEIN E; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; AUTOANTIBODY; EPITOPE; ISOPROSTANE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CONTROLLED STUDY; CROSS BREEDING; DISEASE COURSE; KNOCKOUT MOUSE; LIPID PEROXIDATION; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINE LEVEL;

EID: 0035826892     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.18.2277     Document Type: Article

References (35)

1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
2. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994; 344:793-795.
3. Steinberg D, Witztum JL. Lipoproteins, lipoprotein oxidation and atherogenesis. In: Chien KR, ed. Molecular Basis of Cardiovascular Disease. Philadelphia, Pa: WB Saunders Co; 1999:458-475.
4. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.
5. Watson AD, Leitinger N, Navab M, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272:13597-13607.
6. Heinecke JW. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol. 1997;8: 268-274.
7. Kühn H, Belkner J, Suzuki H, et al. Oxidative modification of human lipoproteins by lipoxygenases of different positional specificities. J Lipid Res. 1994;35:1749-1759.
8. Rankin SM, Parthasarathy S, Steinberg D. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J Lipid Res. 1991;32:449-456.
9. Benz DJ, Mol M, Ezaki M, et al. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J Biol Chem. 1995;270:5191-5197.
10. Ylä-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Nail Acad Sci U S A. 1990;87:6959-6963.
11. Folcik VA, Nivar-Aristy RA, Krajewski LP, et al. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest. 1995;96:504-510.
12. Kühn H, Heydeck D, Hugou I, et al. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J Clin Invest. 1997;99:888-893.
13. Bocan TM, Rosebury WS, Mueller SB, et al. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis. 1998;136:203-216.
14. Cyrus T, Witztum JL, Rader DJ, et al. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice. J Clin Invest. 1999;103:1597-1604.
15. Palinski W, Ord VA, Plump AS, et al. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 1994;14: 605-616.
16. Palinski W, Tangirala RK, Miller E, et al. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15: 1569-1576.
17. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100: 2027-2034.
18. 2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995;332:1198-1203.
19. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998;12:1777-1783.
20. Praticò D, Tangirala RK, Rader DJ, et al. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nat Med. 1998;4:1189-1192.
21. 2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93: 998-1004.
22. 2α-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci U S A. 1998;95:3449-3454.
23. Cole TG, Kitchens R, Daugherty A, et al. An improved method for separation of triglyceride-rich lipoproteins by FPLC. Pharmacia Biocommunique. 1990;4:4-6.
24. Hörkkö S, Miller E, Branch DW, et al. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and β2 glycoprotein 1 (and other proteins). Proc Natl Acad Sci U S A. 1997;94: 10356-10361.
25. 2-isoprostanes in human urine. Proc Natl Acad Sci U S A. 1999;96: 13381-13386.
26. Lawson JA, Rokach J, FitzGerald GA Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem. 1999;274: 24441-24444.
27. 2-isoprostanes in hypercholesterolemia. Circulation. 1998;98: 2822-2828.
28. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Arterloscler Thromb Vasc Biol. 1997;17: 3236-3241.
29. Tangirala RK, Pratico D, FitzGerald GA, et al. Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem. 2001;276:261-266. [e-pub October 9, 2000].
30. 2α) receptor: activation by the isoprostane, 12-iso-PGF2alpha. J Biol Chem. 1997;272:27147-27154.
31. 2 receptor in vivo. Circulation. 2000;101:2833-2839.
32. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell. 1998; 93:229-240.
33. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 1999;400:378-382.
34. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
35. Reaven PD, Napoli C, Merat S, et al. Lipoprotein modification and atherosclerosis in aging. Exp Gerontol. 1999;34:527-539.